27 Apr 2022 by admin in UncategorizedComments Tempest Announces Private Placement Financing of $15 Million
19 Apr 2022 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
30 Mar 2022 by admin in UncategorizedComments Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTA C TM Molecule for the Treatment of Friedreich Ataxia
29 Mar 2022 by admin in UncategorizedComments Tempest Reports Year End 2021 Financial Results and Provides Business Update
24 Mar 2022 by admin in UncategorizedComments Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
16 Mar 2022 by admin in UncategorizedComments Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies
15 Mar 2022 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
15 Mar 2022 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
10 Mar 2022 by admin in UncategorizedComments Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
